AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces